Remission of pure red cell aplasia in T-cell receptor cd-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab Leukemia (2005) T-cell large granular lymphocyte leukemia (T-LGL) is a lymphoproliferative disorder characterized by a persistent increase of peripheral blood large granular lymphocytes and an indolent clinical course with moderate splenomegaly, rheumatoid arthritis and neutropenia. 1 Most cases have a CD3 þ , TCRab þ , CD4À, CD8 þ phenotype, but rare variants may express CD3 and TCRgd epitopes. CD56 and CD57 are variably expressed. Rearrangements of T-cell receptor genes indicate the clonal nature of the disease. In cases requiring therapy, initial treatment consists of cyclosporin A (CSA), methotrexate (MTX) or corticosteroids. 2 Treatment indications include severe neutropenia, anemia, splenomegaly and clinical symptoms.
Some cases of T-LGL are complicated by severe anemia due to pure red cell aplasia (PRCA). 3 PRCA is believed to result from expansion of cytotoxic lymphocytes and is also treated with immunosuppressive therapy including corticosteroids, cyclophosphamide and CSA. Recently, successful therapy of two refractory cases of PRCA with standard doses of anti-CD52 monoclonal antibody (alemtuzumab) has been reported. 4 So far, one patient with T-LGL has been reported who responded to alemtuzumab. 5 In this case, standard doses of Campath-1H were associated with considerable toxicity. 5 Hematologic side effects of alemtuzumab may sometimes require treatment withdrawal. 6 In a recent article published in this journal, Laurenti et al 7 reported rapid immune recovery after low-dose Campath-1H in a group of heavily pretreated patients affected by B-CLL.
Case report
Here, we report successful treatment of pure red cell aplasia with low-dose alemtuzumab in a patient with T-cell receptor gdlarge granular lymphocyte leukemia (TLGLgd) refractory to CSA and MTX treatment. The patient was an 84-year-old Caucasian medical doctor, who was first diagnosed to have T-LGL in June 2003. Over the preceding 9 months, he had experienced a Correspondence slowly developing faintness with extrasystolic rumble and paleness. The patient suffered from chronic obstipation and had lost 3 kg of body weight.
On his first admission, severe anemia with a hemoglobin (Hb) level of 7.0 g/dl was diagnosed.
Peripheral blood counts further showed a leukocytosis (WBC 10.1 Â 10 9 /l, neutrophil count 2.6 Â 10 9 /l, platelets 401 Â 10 9 /l, with absolute lymphocytes 6.5 Â 10 9 /l). Peripheral blood lymphocytes expressed a T-cell phenotype
Bone marrow cytology showed 20% infiltration with mostly mature lymphocytic cells. Bone marrow histology showed a diffuse infiltration with lymphoid cells positive for CD3, CD2 and CD57. Approximately 50% of the cells expressed CD5 and partly CD4 or CD8. The cells were negative for CD56 and LMP-1. A normal XY karyotype was observed. PCR for TCRg was positive. Therefore, the diagnosis of a T-LGLgd was made.
The anemia was classified as PRCA on the basis of low reticulocyte counts 24.1 Â 10 9 /l, considerably reduced erythropoiesis in the bone marrow (ratio of myelopoiesis to erythropoiesis 66 to 6%) and a positive TCRg rearrangement. Peripheral blood erythroid progenitor cells were within the normal range (BFU-E 204/ml; normal range 50-936/ml). LDH was normal and the direct Coombs test was slightly positive (anti-IgG þ ). There were no signs of hemolysis.
Radiological staging showed no hepatosplenomegaly or enlarged lymph nodes.
Treatment
The patient received blood transfusions in intervals of 2-4 weeks (total of 34 units). Treatment with CSA 3 was immediately initiated in June 2003 with target levels of 150-200 ng/ml (Figure 1a) .
Erythropoietin was started simultaneously (3 Â 10 000 U/ week, s.c.). However, no effect on erythropoiesis was seen and CSA therapy was stopped after 4 months. Subsequently, treatment with MTX at a dose of 10 mg/week was started. No effect on reticulocytes, Hb or lymphocytes (Figure 1a-c) was seen and MTX was discontinued after 6 weeks.
Transfusions were continued, while the patient's lymphoma cells were tested for CD52 expression. Immune histologic testing of an iliac crest biopsy sample with monoclonal antibody YTH34.5 showed CD52 expression. Unfortunately, the patient suffered from a herpes zoster infection for the following months, requiring postponement of alemtuzumab therapy. In September 2004, treatment with alemtuzumab was started. At this time, the patient had the following blood count: Hb 7.6 g/dl, with 26.0 Â 10 9 /l reticulocytes and WBC 6.43 Â 10 9 /l. The patient received a dose of 3 mg i.v. on day 1 (September 15, 2004), followed by 10 mg on days 2 and 6 (total dose 23 mg) ( Table 1) .
Toxicity included fever and chills, which were treated with 50 mg of i.v. prednisone on days 1, 2 and 6 (total dose 150 mg). 
Correspondence
No further alemtuzumab was given at this time, because of herpes zoster relapse. The zoster was treated with famciclovir.
A dramatic improvement in blood counts was observed early. Alemtuzumab therapy caused a decrease of lymphocytes from 4.6 Â 10 9 to 0.89 Â 10 9 /l within 6 days. In parallel, the reticulocyte count increased from 26 Â 10 9 to 117 Â 10 9 /l within 7 days indicating erythropoietic regeneration. The Hb increased accordingly (day 30: 10.6 g/dl) (Figure 1a-c) . The patient received a second course of Campath-1H (total dose 23 mg) from October 15 to 17, 2004 (days 31-33). On September 22, after finishing the first course with Campath-1H, our patient had an Hb level of 9.6 g/dl, with a rapid increase of reticulocytes (Figure 1a and b) . 9 /l, platelets 295 Â 10 9 /l). Our case shows that alemtuzumab is highly effective for treatment of therapy-resistant T-LGLgd. Campath-1H treatment has recently been described in another case of T-LGL. 5 Several aspects are remarkable in the case described here.
Alemtuzumab treatment suppressed the leukemic clone within days at doses as low as 23 mg. This small dose followed by one consolidation on day 30 was able to maintain T-LGL in a low steady state for at least 6 months. Since the potential side effects of alemtuzumab including opportunistic infections may particularly influence the outcome of older patients, low-dose treatment could be equally effective as the doses of 360 mg in 12 weeks used in CLL. 8 Alemtuzumab also led to a rapid and sustained elimination of PRCA in our patient. Treatment of PRCA with this antibody has been described for several cases at varying doses (Table 1) . Again, 46 mg was effective enough to keep the patient transfusion independent at almost normal Hb levels assuring a high quality of life.
Toxicity of this treatment was mild except for a herpes zoster relapse, which the patient had also had during therapy with CSA and MTX.
We conclude that low-dose alemtuzumab therapy should be included in the treatment algorithm of T-LGL leukemia, at least when other immunosuppressive regimens have failed. 
